Stemedica
  • About Us
    • Company Overview
  • Technology
    • Manufacturing
    • Our Progenitor Cells
    • Intellectual Property
  • Clinical
    • Clinical Pipeline
    • Clinical Trial Activities
      • Ischemic Stroke
      • Alzheimer’s Disease
    • R&D
  • Media
    • Press Releases
    • Publications
  • Contact
Select Page

Stemedica Cell Technologies Appoints Michael K. Steinhauser CEO and Interim Chairman of the Board

by stemedica admin | May 31, 2023 | Company Initiatives

SAN DIEGO, California –May 31, 2023.  The Board of Directors of Stemedica Cell Technologies, a best-in-class manufacturer of ischemic tolerant stem cells, announced today that it has appointed Michael K. Steinhauser as Chief Executive Officer and Interim Chairman of...

DARIUS ANDERSON TO JOIN STEMEDICA BOARD OF DIRECTORS

by stemedica admin | Mar 30, 2022 | Company Initiatives

Respected and seasoned business leader, investor and political strategist offers multiple talents to stem cell technologies company SAN DIEGO, March 30, 2022 /PRNewswire/ — Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based...

StemProtein Awarded U.S. Patent for Biodegradable Microneedle Device

by stemedica admin | Aug 22, 2021 | Company Initiatives

Dissolvable Needles Allow Dermis Delivery of Proteins and Large Molecules SAN DIEGO — August 23, 2021 — StemProtein, LLC (a subsidiary of Stemedica Cell Technologies, Inc.) a leading manufacturer of physiologically balanced growth factors, exosomes, and...

Stemedica Signs License Agreement with Pulthera, LLC for all Respiratory Indications including those related to COVID-19

by stemedica admin | May 23, 2021 | Company Initiatives

SAN DIEGO, California, May 24, 2021 – Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announced today that it has signed a Licensing Agreement with Pulthera, LLC for the...

President of Leading South Korean Biopharmaceutical Company Green Cross Holdings Joins Stemedica’s Board of Directors

by user | Apr 22, 2014 | Company Initiatives

Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, welcomes Byung-Geon “BG” Rhee, Ph.D., President of Green Cross Holdings, a South Korean biopharmaceutical company, to its board of directors. Green Cross,...

Stemedica Announces New Board Member and Chairman of Audit Committee

by user | Feb 12, 2014 | Company Initiatives

Stemedica announced today that Richard Mejia, Jr. has joined the Company’s Board of Directors and will be Chairman of the Company’s Audit Committee effective January 31, 2014. Mr. Mejia spent 38 years with Ernst & Young, LLP where he was a partner for 25 years. He...
« Older Entries

Categories

  • Clinical Trials
  • Company Initiatives
  • Intellectual Property
  • Manufacturing
  • Partnerships
  • Publications
  • Subsidiaries

Copyright © 2007-2023 Stemedica Cell Technologies, Inc. All rights reserved.
6350 Nancy Ridge Drive, Suite 106, San Diego CA 92121 info@stemedica.com

Privacy Policy